Clinical Trials Directory

Trials / Completed

CompletedNCT00996177

A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously

Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
657 (actual)
Sponsor
Janssen-Cilag International NV · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effectiveness and safety of a patient-controlled system to deliver fentanyl compared with a patient-controlled intravenous system to deliver morphine in the management of postoperative pain.

Detailed description

This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention) study to evaluate the clinical use, safety and ease of care of two patient-controlled analgesia (PCA) systems to deliver pain medication either through the skin or intravenously. The fentanyl hydrochloride PCA system, which delivers the medication through the skin, and morphine intravenous (IV)- PCA, which requires injection into a vein, are used for management of moderate to severe acute pain in postoperative patients who have undergone elective major abdominal or orthopedic surgery. These patients, who are expected to require postoperative pain relief with strong opioids for at least 24 hours, will control the delivery of medication for up to 3 days. Assessment of effectiveness include: patient's global assessment of pain control (poor, fair, good, excellent); Pain Intensity, measured on a visual numerical rating scale from 0 to 10, where 0 means no pain and 10 means the worst possible pain; Ease-of-Care questionnaires including Patient Ease-of-Care questionnaire, Nurse Ease-of-Care questionnaire, and Physical Therapist Ease-of-Care questionnaire; and, total number of doses delivered by patients in the fentanyl transdermal PCA or morphine IV PCA treatment groups. Safety evaluations include vital signs (pulse, blood pressure) and oxygen saturation, respiratory function, and the incidence of adverse events. The study hypothesis is that fentanyl transdermal PCA is not inferior to morphine IV PCA treatment in patient's global assessment of method of pain control during the first 24 hours after surgery. Transdermal PCA: 40 micrograms fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours (maximum of 80 doses, 3.2milligrams). Morphine IV PCA: morphine doses with a maximum of 20 milligrams per 2 hours for 24 hours (maximum 12 doses, 240 milligrams).

Conditions

Interventions

TypeNameDescription
DRUGIONSYS (fentanyl HCl) Iontophoretic TransdermalSystem40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
DRUGIV Morphine Patient-Controlled Analgesia (IV PCA)20mg/2hr (240 mg during 24 hours)

Timeline

Start date
2004-06-01
Primary completion
2005-04-01
Completion
2005-04-01
First posted
2009-10-16
Last updated
2014-01-29

Locations

44 sites across 10 countries: Austria, Belgium, Denmark, France, Germany, Ireland, Spain, Sweden, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00996177. Inclusion in this directory is not an endorsement.

A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously (NCT00996177) · Clinical Trials Directory